Craif and National Cancer Center Hospital sign new joint study agreement to develop a diagnosis method of solid tumors utilizing biological materials such as miRNAs in body fluids

Craif Inc. (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) has entered into a joint study agreement with National Cancer Center Japan (Location: Chuo-ku Tokyo, President: Hitoshi Nakagama). With the conclusion of this agreement, Craif and Department of Experimental Therapeutics (Head of Physicians: Dr. Shunsuke Kondo) of the National Cancer Center Hospital (Director: Kazuaki Shimada) will begin a joint study to develop a diagnosis method of solid tumors.

■ Outline of the study
This study will be enrolled by patients whose solid tumors (stomach cancer, colon cancer, esophageal cancer, pancreatic cancer, liver cancer, bile duct cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, bladder cancer, kidney cancer, etc.) are collected or stored at National Cancer Center Hospital. We aim to identify biomarkers and validate their clinical significance by analyzing biological materials such as exosomal miRNAs captured by Craif’s distinctive  zinc oxide nanowire device.